Pfizer and Nektar reach agreement on Exubera

San Carlos-based Nektar Therapeutics (NKTR) has resolved a contract dispute with Pfizer Inc. (PFE) over its line of inhaled insulin products, the companies announced Tuesday.

Pfizer will pay Nektar $135 million to satisfy its obligations for contracts relating to Exubera, an inhaled insulin product, and agreed to transfer its remaining right to the product if Nektar finds another partner for its development and marketing, the compay said in a statement.

Pfizer announced it would discontinue Exhubera last month due to disappointing sales, taking a $2.8 billion charge in the third quarter as a result, according to the Associated Press.

The companies said they will continue to work together on PEGylated human growth hormone therapy for short stature and growth problems.

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

BART to vote this week on Market Street station canopy project

Shelters for station entrances expected to reduce escalator breakdowns

Thin margin in SF police union election triggers runoff

Police in San Francisco are deeply divided over who should be the… Continue reading

Deal reached to purchase home at center of Moms 4 Housing protest

Oakland Community Land Trust to buy property under agreement with investment firm

Star of 49ers win, Mostert consoled injured teammate: “We’re brothers”

Raheem Mostert, who broke his arm against the Oakland Raiders in 2018, was able to empathize with some of the pain that Coleman was experiencing

Driver fatally strikes pedestrian while fleeing police in Berkeley

A vehicle struck and killed a pedestrian on a sidewalk in Berkeley… Continue reading

Most Read